Aarvik Therapeutics Inc’s Post

Our sincere thanks to Aarvik Employees, Board Members, Scientific Advisory Board members, Collaborators and Investors for their commitment and excellent work, guidance and support towards making another outstanding year in building Aarvik's Discovery Portfolio. We look forward to another exciting year. Happy Holidays and a Happy New Year. Image Courtesy: Allison Bruce

The Aarvik Therapeutics Inc team has put together an extensive review of the "Clinical Landscape of Antibody-Drug Conjugates (ADCs). This review has a focus on discontinued ADCs from the clinic, to learn lessons from them and to enable Next-Generation ADCs. Special thanks to Heather Maecker and Vidya Jonnalagadda for the countless hours spent in compiling this review article. Our sincere thanks to Hanson Wade Group for providing access to the Beacon Targeted Therapies Clinical Trials and Pipeline Database. We could not cite every possible reference in the ADC field because of reference limit in the review article. https://lnkd.in/ehyghuMc